Hymecromone-SZ, tablets 200 mg 50 pcs

Pharmacotherapeutic group: choleretic remedy.

ATX code: A05AX02

Pharmacological properties

Pharmacodynamics

Bile diuretic. Increases formation and secretion of bile. It has a selective antispasmodic effect on the bile ducts and sphincter of Oddi (does not decrease peristalsis of the gastrointestinal tract (GIT) and blood pressure (BP)). It reduces bile stasis, prevents cholesterol crystallization and thereby development of cholithiasis.

Pharmacokinetics

In oral administration it is easily absorbed from digestive tract, it is weakly bound to plasma proteins. Maximal concentration in serum is reached after 2-3 hours. The elimination half-life is about 1 hour. Hymecromone is excreted by the kidneys (about 93% as glucuronate, 1.4% as sulfonate, 0.3% – unchanged).

Indications

Biliary dyskinesia and Oddi sphincter hyperkinetic type, noncalculous chronic cholecystitis, cholangitis, cholelithiasis; condition after surgical interventions on gallbladder and biliary tracts. Appetite decrease, nausea, constipation, vomiting (against hyposecretion of bile).

Active ingredient

Hymecromone

Composition

On one tablet:

the active substance:

hymecromone – 200 mg;

excipients:

potato starch – 45.0 mg,

gelatin -3.0 mg,

sodium lauryl sulfate – 1.0 mg,

magnesium stearate – 1.0 mg.

How to take, the dosage

Orally, 30 minutes before a meal; adults – 200-400 mg (1-2 tablets) three times a day.

The daily dose is 1200 mg.

Children over 7 years old – 200 mg (1 tablet) once or three times a day.

The daily dose is 600 mg.

The course of treatment is two weeks.

In case the dose is missed it should be taken as soon as possible or if the next dose is coming up do not take the missed dose. Do not take a double dose at once.

If after treatment there is no improvement or the symptoms worsen or new symptoms appear, it is necessary to consult a doctor. Use the drug only according to the indications, the method of administration and in the doses specified in the instructions.

Interaction

Morphine weakens the effects of gimecromone.

When combined with metoclopramide there is a weakening of the effects of both drugs

It enhances the effects of indirect anticoagulants.

Special Instructions

It does not impair the secretory function of the digestive glands and intestinal absorption processes.

Influence on ability to drive vehicles, machinery

The drug Gymecromon-SZ has no effect on the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

Contraindications

Hypersensitivity.

Biliary obstruction, renal/liver failure, ulcerative colitis, Crohn’s disease, peptic ulcer and duodenal disease, hemophilia.

Children under 7 years.

Side effects

Allergic reactions; diarrhea, flatulence, abdominal pain, gastrointestinal mucosa ulceration, headache are possible.

If you have side effects mentioned in the instruction or they are aggravated, or if you notice any other side effects not specified in the instruction, inform your doctor.

Overdose

To date, no cases of overdose have been reported.

Pregnancy use

There are no data on the safety of use of Gymecromone in pregnancy and during breastfeeding. Use of the drug Gymecromon-SZ during pregnancy and breastfeeding is allowed by prescription only in cases when the potential benefit to the mother exceeds the potential risk to the fetus and child.